Who we are…
- Senior Pharmaceutical Executives with success in start-ups, growth and large scale business
- Hands-on, diversified and driven
- Global experiences with a US generic market focus
What we bring…
- Expertise in the life sciences and adjacent businesses
- Agile business structure with a drive for success
- Ability to quickly leverage global resources at a local level
Daniel Carbery is the President and General Manager of Amring. He is responsible for creating the strategic vision and operating plan for the company. Mr. Carbery is charged with driving a talented leadership team to build a new generic drug company, one that’s based on high quality products, committed employees, enduring and trusting customer relationships, global business partnerships and complete integrity.
Mr. Carbery has a successful track record building and leading franchises and serving a national consumer audience through health care and retail distribution channels. Before becoming a founding leader and head of Amring, Mr. Carbery was Chief Executive Officer and Board Director for Axcentria Pharmaceuticals. Previously, he held positions of increasing managerial and executive responsibility for companies including Endo Pharmaceuticals, Procter & Gamble, Nabisco and GlaxoSmithKline.
Mr. Carbery has expertise in commercial management, product development, and total supply chain activities at the national and global levels. He has proved to be a sophisticated strategist and an expert at leading operations across a range of functions, including R&D, engineering, plant operations, marketing, product development and market development. Mr. Carbery has provided strategic and business counsel to major organizations and startups.
Mr. Carbery graduated from Princeton University with a degree in Chemical Engineering and earned his MBA from Rutgers University.
As Head, Sales and Marketing, Mr. Sammler is responsible for the strategy and tactical execution of the Amring commercial product portfolio. He leads the identification and pursuit of profitable sales growth at the national, regional, and local level, across Retail, Specialty and Institutional Pharmacy. He also helps carry out growth initiatives, such as business development activities, to ensure strong, sustained P&L performance for the company.
Before joining Amring in September 2015, Mr. Sammler was Director, Sales Operations for Impax Laboratories. In that position, he managed sales operations during the company’s integration with the Tower Holding companies. Previously, Mr. Sammler held various marketing and financial positions at CorePharma, Sandoz, Endo Pharmaceuticals and DuPont/DuPont Merck. He has experience driving revenues for both generic and branded pharmaceutical products and leading a diverse range of commercial operations, from sales teams and product marketing to supply chain logistics and strategic planning.
Mr. Sammler graduated with a B.S. in Accounting from Widener University and earned his MBA in Pharmaceutical Marketing from Saint Joseph’s University.
Rich Ciamacca is Vice President, Secretary and General Counsel of Amring. He oversees all legal matters for the company, including contractual agreements, corporate governance, and compliance matters. He also provides legal advice to the President on issues such as quality, supply chain, finance, sales and marketing. He is responsible for building the pharmacovigilance and government pricing functions at the company, managing outside counsel, and performing due diligence for business development opportunities.
Mr. Ciamacca has more than 22 years of experience representing major pharmaceutical research companies and organizations in regulated industries. He came to Amring from Axiom, where he served as interim General Counsel. Prior to that Mr. Ciamacca worked for Actelion as Corporate Secretary and Senior Legal Counsel for the US research and development affiliate.
Mr. Ciamacca holds a B.S. in Science from Penn State University and earned his law degree from Villanova University. Before earning his law degree, Mr. Ciamacca was a submarine officer for the U.S. Navy and an inspection supervisor and quality and test engineer in the defense industry for Lockheed and Raytheon.
Erika Geimonen serves as Vice President, Business Development for Amring Pharmaceuticals. She is responsible for analyzing the market landscape to identify opportunities in product licensing, partnering and acquisitions that will help Amring Pharmaceuticals reach its strategic objectives. She evaluates the company’s business development opportunities, including M&A, in-licensing, divestment, alliances and out-licensing. She also leads the due diligence team that oversees all company acquisitions.
Dr. Geimonen has more than 23 years of experience in business development and research. Before joining Amring Pharmaceuticals, she was the Chief Operating Officer and Vice President, Business Development for Dynamis Therapeutics. In that position, she was responsible for all business development activities, managing operations, and raising capital for the company. Previously, Dr. Geimonen held business development positions at XBiotech, Luitpold Pharmaceuticals and Schering-Plough. Earlier in her career Dr. Geimonen held a series of research roles.
Dr. Geimonen co-chairs the Philadelphia chapter of Licensing Executives Society. She earned her M.S. in Biology and Ph.D. in Biology and Biochemistry from Moscow State University in Russia and an M.S. in Management and Policy from the College of Business at the State University of New York at Stony Brook.
Paul Nelson is responsible for the supply of all Amring products. Mr. Nelson oversees procurement, contracts with external suppliers and CMOs, as well as the inventory and logistics that allow Amring to provide quality products to patients. He works with the Business Development organization and conducts due diligence on potential new business partners and product licensing opportunities. He also partners with Sales and Marketing to ensure that the company maintains and forecasts adequate inventory for all its products, addresses supply issues, and optimizes product performance in terms of delivery, margin, cost, inventory and quality.
Mr. Nelson came to Amring in late 2015 from Auxilium Pharmaceuticals, where he developed the supply chain strategy and led supply chain operations for all commercial products, including oral solid dose and capsule products, large-molecule parenteral products, and medical devices. Previously, he held leadership positions at Shire and UCB. He has experience in end-to-end supply chain management and understands how to implement strategies that allow for rapid growth and respond to ever-changing business conditions.
Mr. Nelson is a member of the Integrity of Supply working group, a team co-sponsored by the U.S. Food and Drug Administration and Xavier University that aims to develop and implement Good Supply Practices (GSPs). He is a member of and speaker for the International Quality and Productivity Center, a leading lean six sigma advocacy group. Mr. Nelson holds degrees in Applied Mathematics from Kentucky State University and Chemical Engineering from the University of Kentucky, as well as an MBA from University of South Carolina.
Zahid Muhammad manages all aspects of Quality Assurance & Regulatory Affairs for Amring and provides oversight to ensure compliance to cGMPs and Amring’s policies. Mr. Muhammad oversees Quality for the R&D portfolio for generic drug candidates from product development, technical transfer, regulatory submission through commercial manufacturing, release and distribution. Mr. Muhammad is responsible for interacting with internal and external stakeholders, including FDA, to help bring new Amring products to market.
Mr. Muhammad is a quality assurance professional with 24 years of experience and comprehensive knowledge of quality management systems, quality risk management, quality by design, CDMO selection & oversight, product development, analytical method development, QC testing, validation and global product tech transfers.
Mr. Muhammad holds a Master’s in Industrial Chemistry, a Master’s in Physical Analytical Chemistry from the City University of New York(CUNY), and an MBA from the New York Institute of Technology(NYIT).
Tatyana Kosheleva is Head, Finance and Corporate Treasurer for Amring Pharmaceuticals Inc. In this role, Ms. Kosheleva is responsible for supporting the company’s financial growth. She oversees forecasting and planning, accounting, liquidity management, internal controls, compliance, purchasing, and bank and audit relationship management. Ms. Kosheleva is a member of Amring’s Executive Board, and reports directly to the President of Amring.
Ms. Kosheleva has extensive international financial and operational expertise, with a career that spans more than two decades and four countries. Before joining Amring, she was Finance Director at Russian subsidiary of Ferring Pharmaceuticals. Prior to that, Ms. Kosheleva served as Chief Financial Officer at DST Global Solutions, a London-based subsidiary of DST Systems, with offices in nine countries.
Ms. Kosheleva is a licensed CPA and holds an MBA from Thunderbird School of Global Management, a part of the Arizona State University.